Wall Street Breakfast Podcast: CAVA Slides On Sales Miss

CAVA Group shares plummeted 22% premarket following Q2 results that, despite topping adjusted EBITDA and EPS estimates, revealed disappointing 2.1% same-restaurant sales growth against a 6.1% consensus, prompting a cut to 2025 comparable sales guidance and raising concerns about traffic and future expansion. Separately, Brazil announced a $5.6 billion aid package for exporters to mitigate the impact of new U.S. tariffs, while Sam Altman is reportedly backing Merge Labs, a new brain-computer interface startup aiming to raise $250 million to compete with Neuralink.

Analysis

CAVA Group (CAVA) is experiencing a significant market repricing, evidenced by a 22% premarket stock decline, despite beating consensus on adjusted EBITDA and EPS. The severe negative reaction is driven by a critical miss on same-restaurant sales growth, which came in at 2.1% versus a 6.1% estimate, and a concerning detail that guest traffic was approximately flat. This indicates that revenue growth is heavily reliant on new store openings and price increases rather than organic demand at existing locations. Consequently, management has lowered its 2025 comparable sales growth forecast from a range of +6.0%-8.0% to +4.0%-6.0% and reduced its new restaurant opening guidance, signaling a material slowdown in its growth trajectory. In geopolitical news, Brazil has initiated a $5.6 billion aid package to support its exporters against new 50% U.S. tariffs, a defensive measure to mitigate economic damage, although key sectors like orange juice and aircraft are exempt. In the technology sector, competition in the brain-computer interface space is intensifying as OpenAI co-founder Sam Altman is reportedly backing Merge Labs. The new venture is seeking to raise approximately $250 million, positioning it as a formidable, well-capitalized rival to Elon Musk's Neuralink and validating growing investor interest in the neurotech field.

Key Decisions for Investors

• For CAVA Group, the significant miss on same-restaurant sales and the subsequent guidance cut materially weaken the company's high-growth narrative; investors should exercise caution and monitor for a stabilization or recovery in guest traffic before re-evaluating the stock's long-term prospects.
• The emergence of Merge Labs, backed by OpenAI's venture arm, signals an acceleration of capital and competition in the brain-computer interface market, warranting attention from investors in the broader AI and neurotechnology space as a key developing theme.
• Investors with exposure to Brazilian export-oriented companies should assess the impact of new U.S. tariffs, noting that the government's $5.6 billion aid package may provide a partial buffer for affected firms, though heightened trade policy risk remains a key factor.
• Given the options market is implying a 6% move for Cisco (CSCO) post-earnings and its supplier Fabrinet (FN) has historically traded in tandem, event-driven investors may consider strategies to capitalize on potential volatility.